心力衰竭的进展:新疗法的更新

M. Silver
{"title":"心力衰竭的进展:新疗法的更新","authors":"M. Silver","doi":"10.1111/J.1527-5299.2005.04779.X","DOIUrl":null,"url":null,"abstract":"Marc A. Silver, MD, Co-Editor in Chief From the Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL Address for correspondence: Marc A. Silver, MD, Chairman and Clinical Professor, Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, 4440 West 95th Street, Suite 319 South, Oak Lawn, IL 60453-2600 E-mail: marc.silver@advocatehealth.com In January 2005, we issued a call for papers to focus on updates on some of the new and emerging therapies for patients with heart failure. We specifically asked potential authors to focus on biventricular resynchronization and left ventricular assist devices. This focus was prudent, because although clinical trial publications and early adoption of these strategies were of recent vintage, we felt that these were two key therapeutic areas where the field was evolving on a daily basis. Furthermore, as a heart failure community, we must test our tools every day. There is no room here for a strategy or therapy that does not provide continued significant improvement in heart failure outcomes for patients. So the call went out and authors responded. Included in this issue are four of these papers. One deals with updates on selecting responders to resynchronization therapy—a hot topic indeed. Two others deal with advances in patient selection and care for potential left ventricular assist device recipients and potential new complications to be aware of. We are also pleased to have the excellent paper by Faris and colleagues representing an important FDA perspective on both resynchronization and left ventricular assist devices. And as these papers are published, it is my hope that they soon become obsolete. We should push ourselves to test the methods and resources we use for heart failure patients every day. We should continue to speak among ourselves and to others about these advances. In that context, Congestive Heart Failure will continue to publish periodic focus issues like this. In an electronic age, we should be able to spread best practices liberally to those who provide the care; it is our pledge to be part of that dissemination of current knowledge.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"18 1","pages":"176-176"},"PeriodicalIF":0.0000,"publicationDate":"2005-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Advancing the Advances in Heart Failure: Updates on Newer Therapies\",\"authors\":\"M. Silver\",\"doi\":\"10.1111/J.1527-5299.2005.04779.X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Marc A. Silver, MD, Co-Editor in Chief From the Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL Address for correspondence: Marc A. Silver, MD, Chairman and Clinical Professor, Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, 4440 West 95th Street, Suite 319 South, Oak Lawn, IL 60453-2600 E-mail: marc.silver@advocatehealth.com In January 2005, we issued a call for papers to focus on updates on some of the new and emerging therapies for patients with heart failure. We specifically asked potential authors to focus on biventricular resynchronization and left ventricular assist devices. This focus was prudent, because although clinical trial publications and early adoption of these strategies were of recent vintage, we felt that these were two key therapeutic areas where the field was evolving on a daily basis. Furthermore, as a heart failure community, we must test our tools every day. There is no room here for a strategy or therapy that does not provide continued significant improvement in heart failure outcomes for patients. So the call went out and authors responded. Included in this issue are four of these papers. One deals with updates on selecting responders to resynchronization therapy—a hot topic indeed. Two others deal with advances in patient selection and care for potential left ventricular assist device recipients and potential new complications to be aware of. We are also pleased to have the excellent paper by Faris and colleagues representing an important FDA perspective on both resynchronization and left ventricular assist devices. And as these papers are published, it is my hope that they soon become obsolete. We should push ourselves to test the methods and resources we use for heart failure patients every day. We should continue to speak among ourselves and to others about these advances. In that context, Congestive Heart Failure will continue to publish periodic focus issues like this. In an electronic age, we should be able to spread best practices liberally to those who provide the care; it is our pledge to be part of that dissemination of current knowledge.\",\"PeriodicalId\":10536,\"journal\":{\"name\":\"Congestive heart failure\",\"volume\":\"18 1\",\"pages\":\"176-176\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Congestive heart failure\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/J.1527-5299.2005.04779.X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Congestive heart failure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1527-5299.2005.04779.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

马克·a·西尔弗,医学博士,联合主编来自医学系和心力衰竭研究所,倡导基督医疗中心,橡树草坪,IL通信地址:马克·a·西尔弗,医学博士,医学和心力衰竭研究所系主任和临床教授,倡导基督医疗中心,西95街4440号,套房319南,橡树草坪,IL 60453-2600电子邮件:marc.silver@advocatehealth.com在2005年1月,我们发布了一项论文征集,聚焦于一些新的和新兴的治疗心力衰竭的方法。我们特别要求潜在的作者关注双心室再同步和左心室辅助装置。这种关注是谨慎的,因为尽管临床试验出版物和这些策略的早期采用是最近的,但我们认为这是该领域每天都在发展的两个关键治疗领域。此外,作为一个心力衰竭社区,我们必须每天测试我们的工具。对于不能持续显著改善心力衰竭患者预后的策略或治疗,我们没有立足之地。于是这个号召发出了,作者们也回应了。本期将收录其中的四篇论文。其中一篇是关于选择再同步治疗应答者的最新进展——这确实是一个热门话题。另外两篇涉及到患者选择和护理的进展,潜在的左心室辅助装置接受者和潜在的新并发症要注意。我们也很高兴Faris及其同事发表了一篇优秀的论文,代表了FDA对再同步化和左心室辅助装置的重要观点。随着这些论文的发表,我希望它们很快就会过时。我们应该督促自己每天测试治疗心力衰竭患者的方法和资源。我们应该继续在我们自己和其他人之间谈论这些进步。在这样的背景下,《充血性心力衰竭》将继续定期出版这样的焦点问题。在电子时代,我们应该能够将最佳实践自由地传播给提供护理的人;我们保证成为传播当前知识的一部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Advancing the Advances in Heart Failure: Updates on Newer Therapies
Marc A. Silver, MD, Co-Editor in Chief From the Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn, IL Address for correspondence: Marc A. Silver, MD, Chairman and Clinical Professor, Department of Medicine and the Heart Failure Institute, Advocate Christ Medical Center, 4440 West 95th Street, Suite 319 South, Oak Lawn, IL 60453-2600 E-mail: marc.silver@advocatehealth.com In January 2005, we issued a call for papers to focus on updates on some of the new and emerging therapies for patients with heart failure. We specifically asked potential authors to focus on biventricular resynchronization and left ventricular assist devices. This focus was prudent, because although clinical trial publications and early adoption of these strategies were of recent vintage, we felt that these were two key therapeutic areas where the field was evolving on a daily basis. Furthermore, as a heart failure community, we must test our tools every day. There is no room here for a strategy or therapy that does not provide continued significant improvement in heart failure outcomes for patients. So the call went out and authors responded. Included in this issue are four of these papers. One deals with updates on selecting responders to resynchronization therapy—a hot topic indeed. Two others deal with advances in patient selection and care for potential left ventricular assist device recipients and potential new complications to be aware of. We are also pleased to have the excellent paper by Faris and colleagues representing an important FDA perspective on both resynchronization and left ventricular assist devices. And as these papers are published, it is my hope that they soon become obsolete. We should push ourselves to test the methods and resources we use for heart failure patients every day. We should continue to speak among ourselves and to others about these advances. In that context, Congestive Heart Failure will continue to publish periodic focus issues like this. In an electronic age, we should be able to spread best practices liberally to those who provide the care; it is our pledge to be part of that dissemination of current knowledge.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信